SCHEMBL4723585

SCHEMBL4723585

CCCCOc1c(-c2ccccc2)[c]nc2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 1/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
DHODH Q02127 1/20 0.40
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GAA P10253 2/20 0.38
PLA2G2A P14555 1/20 0.38
ACP1 P24666 1/20 0.37
LTA4H P09960 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
TP53 P04637 2/20 0.36
MPO P05164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724169 0.93 MAPT (0.40) ALDH1A1LMNAMAPTKDM4EHPGD
SCHEMBL4724201 0.87 KMT2A (0.40) L3MBTL1ALDH1A1LMNAMAPTKDM4E
SCHEMBL4720694 0.82 L3MBTL1 (0.40) L3MBTL1ALDH1A1LMNANPY1RNPY2R
SCHEMBL577791 0.79 POLB (0.55) L3MBTL1ALDH1A1LMNAMAPTKDM4E
SCHEMBL19583344 0.77 POLB (0.55) L3MBTL1ALDH1A1LMNANPY1RNPY2R
SCHEMBL4721248 0.75 TLR8 (0.37) L3MBTL1ALDH1A1LMNAMAPTKDM4E
SCHEMBL3769443 0.70 CREB1 (0.40) ALDH1A1LMNAMAPTGAALTA4H
SCHEMBL29363526 0.69 LTA4H (0.52) L3MBTL1ALDH1A1MAPTKDM4EHPGD
SCHEMBL442080 0.69 LTA4H (0.52) L3MBTL1ALDH1A1MAPTKDM4EHPGD
SCHEMBL3343356 0.69 POLB (0.57) L3MBTL1ALDH1A1LMNANPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 L3MBTL1 3954/4885ALDH1A1 622/4885LMNA 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.